Social Evaluated Cold Pressor Test in Hereditary Angioedema Patients (FROSEN)
Functional Physiological, Psychological and Biochemical Reactivity to Social Evaluated Cold Pressor Test in Hereditary Angioedema Patients
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Milan, Italy, 20138
- Istituti Clinici Scientifici Maugeri
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Documented diagnosis of hereditary angioedema due to C1 inhibitor deficiency aged between 18 and 65 years (for the group of patients)
Exclusion Criteria:
- Any type of chronic disease requiring chronic treatment (i.e. hypertension, previous myocardial infarction, diabetes, chronic heart failure, autoimmune disease, neurodegenerative disease)
- Active acute disease;
- Sars-Cov2 infection in the previous 3 months.
- An acute attack experienced within the previous week and within 72 hours after the registration (a posteriori exclusion).
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Healthy individuals
Healthy individuals with an age between 18 and 65 and matched with patients with hereditary angioedema by age and gender.
|
|
Patients with hereditary angioedema
Patients with documented diagnosis of hereditary angioedema due to C1 inhibitor deficiency and aged between 18 and 65 years.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Heart rate
Time Frame: Baseline
|
Changes in the heart rate (beats per minute) from resting to SECPT condition
|
Baseline
|
|
Systolic arterial pressure
Time Frame: Baseline
|
Changes in the systolic blood pressure (mmHg) from resting to SECPT condition
|
Baseline
|
|
Diastolic arterial pressure
Time Frame: Baseline
|
Changes in the systolic blood pressure (mmHg) from resting to SECPT condition
|
Baseline
|
|
Visual Analogue Scale of perceived stress
Time Frame: Baseline
|
Changes in the perceived stress due to SECP.
Scores ranges from 0 (no stress) to 100 (worst stress possible)
|
Baseline
|
|
Concentration of inflammatory cytokines
Time Frame: Baseline
|
Changes in the concentration of inflammatory cytokines (pg/ml) due to SECPT
|
Baseline
|
|
Concentration of plasma cathecolamines
Time Frame: Baseline
|
Changes in the concentration of plasma cathecolamines (pg/ml) due to SECPT
|
Baseline
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hospital Anxiety and Depression Scale
Time Frame: Baseline
|
A 14-item questionnaire subdivided in two subscales to measure anxiety and depression.
Scores for each subscale ranges from 0 (absence of symptoms) to 21 (significant symptoms)
|
Baseline
|
|
Perceived Stress Scale (PSS-10)
Time Frame: Baseline
|
A 10-item questionnaire to measure stress levels related to the perception of unpredicable, uncontrollable, and overloading nature of life.
Scores ranges from 0 (low levels) to 40 (high levels).
|
Baseline
|
|
Multidimensional Assessment of Interoceptive Awareness Version 1
Time Frame: Baseline
|
A 32-item questionnaire to measure Interoceptive Awareness.
Scores ranges from 0 (low interoceptive awareness) to 160 (high interoceptive awareness).
|
Baseline
|
|
Body Appreciation Scale-2 (BAS-2)
Time Frame: Baseline
|
A 10-item questionnaire to measure appreciation.
Scores ranges from 10 (low body appreciation) to 50 (high body appreciation).
|
Baseline
|
|
Functionality Appreciation Scale (FAS)
Time Frame: Baseline
|
A 7-item questionnaire to measure body appreciation.
Scores ranges from 0 (low functionality appreciation) to 35 (high functionality appreciation)
|
Baseline
|
|
Pain Catastrophizing Scale (PCS)
Time Frame: Baseline
|
A 13-item questionnaire to measure pain-related catastrophizing.
Scores ranges from 0 (low catastrophizing ) to 52 (high catastrophizing).
|
Baseline
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Skin Diseases
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Hypersensitivity, Immediate
- Genetic Diseases, Inborn
- Skin Diseases, Vascular
- Hypersensitivity
- Urticaria
- Hereditary Complement Deficiency Diseases
- Primary Immunodeficiency Diseases
- Angioedema
- Angioedemas, Hereditary
Other Study ID Numbers
Other Study ID Numbers
- 2774CE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.